CVB homepage

JenaValve's Trilogy Transcatheter Heart Valve, the only TAVR device approved by the FDA for treating aortic regurgitation, may offer hope for high-risk LVAD patients in need of aortic valve replacement. Additional follow-up data are still necessary, researchers emphasized. 

FDA Recall

The recall was initiated due to a risk of metal contamination that could potentially injure a patient. At this time, however, no adverse events have been reported.

Technologist scans a patient at Wellstar Kennestone Hospital. Photo by Dave Fornell

Voters in Broward County, Florida, have agreed to fund a CCTA screening program after a pilot study linked the practice to considerable benefits. "This is actually very big news and will save thousands of lives," one local imaging specialist said. 

MiniMed Fit

The MiniMed Fit is indicated for patients 7 years old and older with type 1 or type 2 diabetes. This represents the second FDA clearance for a tubeless automated insulin delivery system in a matter of days.

American College of Cardiology President Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI, and professor of medicine at Icahn School of Medicine at Mount Sinai, gave a key note presentation on coronary inflammation at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 meeting. She said inflammation is a growing area of interest as new drugs work their way through trials and clinicians learn the important of using existing methods to lower this residual risk factor for heart disease.

Coronary inflammation may play a critical role in the prevention and treatment of cardiovascular disease. American College of Cardiology President Roxana Mehran, MD, spoke to Cardiovascular Business about this topic at TCT 2026.

Shahab Moossavi, MD

Shahab Moossavi, MD, is remembered as a "dedicated physician who made a meaningful difference in the lives of his patients and the colleagues who worked alongside him." He was 51 years old.

Innovation at work

Nearly half of all American adults over the age of 20 have hypertension, and they face an increased risk of cardiovascular disease, renal events and cerebrovascular events. The recent rise of renal denervation has given cardiologists a new way to fight back against this trend.

Sponsored by Recor Medical

Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.